- Home
- QNCX vs NXC Comparison
QNCX vs NXC Comparison
Compare QNCX & NXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- NXC
- Stock Information
- Founded
- QNCX 2012
- NXC 1992
- Country
- QNCX United States
- NXC United States
- Employees
- QNCX N/A
- NXC N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- NXC Investment Managers
- Sector
- QNCX Health Care
- NXC Finance
- Exchange
- QNCX Nasdaq
- NXC Nasdaq
- Market Cap
- QNCX 47.7M
- NXC 84.3M
- IPO Year
- QNCX 2019
- NXC N/A
- Fundamental
- Price
- QNCX $2.00
- NXC $12.97
- Analyst Decision
- QNCX Strong Buy
- NXC
- Analyst Count
- QNCX 5
- NXC 0
- Target Price
- QNCX $8.00
- NXC N/A
- AVG Volume (30 Days)
- QNCX 374.6K
- NXC 17.5K
- Earning Date
- QNCX 08-12-2025
- NXC 01-01-0001
- Dividend Yield
- QNCX N/A
- NXC 3.97%
- EPS Growth
- QNCX N/A
- NXC N/A
- EPS
- QNCX N/A
- NXC 0.19
- Revenue
- QNCX N/A
- NXC N/A
- Revenue This Year
- QNCX N/A
- NXC N/A
- Revenue Next Year
- QNCX N/A
- NXC N/A
- P/E Ratio
- QNCX N/A
- NXC $70.47
- Revenue Growth
- QNCX N/A
- NXC N/A
- 52 Week Low
- QNCX $0.51
- NXC $11.86
- 52 Week High
- QNCX $2.45
- NXC $13.70
- Technical
- Relative Strength Index (RSI)
- QNCX 70.90
- NXC 53.92
- Support Level
- QNCX $1.55
- NXC $12.88
- Resistance Level
- QNCX $1.71
- NXC $13.04
- Average True Range (ATR)
- QNCX 0.15
- NXC 0.13
- MACD
- QNCX 0.02
- NXC -0.00
- Stochastic Oscillator
- QNCX 89.09
- NXC 49.04
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.